Orphan drug designation granted for the treatment of leukemia.
In: Proteomics Weekly, 2004-11-22, S. 120-121
serialPeriodical
Zugriff:
The article reports that Kosan Biosciences Inc. has announced that the U.S. Food and Drug Administration has granted its anticancer compound 17-allylamino-17-demethoxy-geldanamycin, or 17-AAG, an analog of the polyketide geldanamycin, orphan drug status for the treatment of chronic myelogenous leukemia (CML). Chronic myelogenous leukemia, or CML, often referred to as chronic myeloid leukemia is a cancer of the blood system in which too many white blood cells are produced in the bone marrow.
Titel: |
Orphan drug designation granted for the treatment of leukemia.
|
---|---|
Zeitschrift: | Proteomics Weekly, 2004-11-22, S. 120-121 |
Veröffentlichung: | 2004 |
Medientyp: | serialPeriodical |
ISSN: | 1535-2722 (print) |
Sonstiges: |
|